Impact of comorbidity on risk of venous thromboembolism in patients with breast cancer: a Danish population-based cohort study

Anne Gulbech Ording; Erzsébet Horváth-Puhó; Jens Peter Garne; Petra Witt Nyström; Mogens Vyberg; Henrik Toft Sørensen; Timothy L Lash

doi:10.1136/bmjopen-2014-005082

Impact of comorbidity on risk of venous thromboembolism in patients with breast cancer: a Danish population-based cohort study

Anne Gulbech Ording, Erzsébet Horváth-Puhó, Jens Peter Garne, Petra Witt Nyström, Mogens Vyberg, Henrik Toft Sørensen, Timothy L Lash

Research output: Contribution to journal › Journal article › Research › peer-review

10 Citations (Scopus)

Abstract

OBJECTIVES: To assess the interaction between comorbidity and breast cancer (BC) on the rate of venous thromboembolism (VTE) beyond what can be explained by the independent effects of BC and comorbidity.

DESIGN: Population-based matched cohort study.

SETTING: Denmark.

PARTICIPANTS: Danish patients with BC (n=62 376) diagnosed in 1995-2010 and a comparison cohort of women without BC (n=304 803) from the general population were matched to the patients with BC on year of birth in 5-year intervals and on the specific diseases included in the Charlson Comorbidity Index (CCI) and atrial fibrillation and obesity.

MEASURES: The rate ratios of VTE per 1000 person-years (PY) were computed by comorbidity levels using the CCI, and interaction contrasts (IC) were calculated as a measure of the excess or deficit VTE rate not explained by the independent effects of BC and comorbidity.

RESULTS: Among patients with BC with a CCI score of 1, the 0-1 year VTE rate was 12/1000 PY, and interaction accounted for 10% of the rate (IC=3.2, 95% CI 0.5 to 5.9). Among patients with BC with CCI ≥4, the VTE rate was 17, and interaction accounted for 8% of the rate (IC=1.2, 95% CI -1.8 to 4.2). There was no interaction during 2-5 years of follow-up.

CONCLUSIONS: There was only little interaction between BC and the CCI score on the rate of VTE.

Original language	English
Journal	BMJ Open
Volume	4
Issue number	6
Pages (from-to)	e005082
ISSN	2044-6055
DOIs	https://doi.org/10.1136/bmjopen-2014-005082
Publication status	Published - 2014

Access to Document

10.1136/bmjopen-2014-005082

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{63f21873d6114a0084dde961613be3ce,

title = "Impact of comorbidity on risk of venous thromboembolism in patients with breast cancer: a Danish population-based cohort study",

abstract = "OBJECTIVES: To assess the interaction between comorbidity and breast cancer (BC) on the rate of venous thromboembolism (VTE) beyond what can be explained by the independent effects of BC and comorbidity.DESIGN: Population-based matched cohort study.SETTING: Denmark.PARTICIPANTS: Danish patients with BC (n=62 376) diagnosed in 1995-2010 and a comparison cohort of women without BC (n=304 803) from the general population were matched to the patients with BC on year of birth in 5-year intervals and on the specific diseases included in the Charlson Comorbidity Index (CCI) and atrial fibrillation and obesity.MEASURES: The rate ratios of VTE per 1000 person-years (PY) were computed by comorbidity levels using the CCI, and interaction contrasts (IC) were calculated as a measure of the excess or deficit VTE rate not explained by the independent effects of BC and comorbidity.RESULTS: Among patients with BC with a CCI score of 1, the 0-1 year VTE rate was 12/1000 PY, and interaction accounted for 10% of the rate (IC=3.2, 95% CI 0.5 to 5.9). Among patients with BC with CCI ≥4, the VTE rate was 17, and interaction accounted for 8% of the rate (IC=1.2, 95% CI -1.8 to 4.2). There was no interaction during 2-5 years of follow-up.CONCLUSIONS: There was only little interaction between BC and the CCI score on the rate of VTE.",

author = "Ording, {Anne Gulbech} and Erzs{\'e}bet Horv{\'a}th-Puh{\'o} and Garne, {Jens Peter} and Nystr{\"o}m, {Petra Witt} and Mogens Vyberg and S{\o}rensen, {Henrik Toft} and Lash, {Timothy L}",

note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.",

year = "2014",

doi = "10.1136/bmjopen-2014-005082",

language = "English",

volume = "4",

pages = "e005082",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Group",

number = "6",

}

TY - JOUR

T1 - Impact of comorbidity on risk of venous thromboembolism in patients with breast cancer

T2 - a Danish population-based cohort study

AU - Ording, Anne Gulbech

AU - Horváth-Puhó, Erzsébet

AU - Garne, Jens Peter

AU - Nyström, Petra Witt

AU - Vyberg, Mogens

AU - Sørensen, Henrik Toft

AU - Lash, Timothy L

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2014

Y1 - 2014

N2 - OBJECTIVES: To assess the interaction between comorbidity and breast cancer (BC) on the rate of venous thromboembolism (VTE) beyond what can be explained by the independent effects of BC and comorbidity.DESIGN: Population-based matched cohort study.SETTING: Denmark.PARTICIPANTS: Danish patients with BC (n=62 376) diagnosed in 1995-2010 and a comparison cohort of women without BC (n=304 803) from the general population were matched to the patients with BC on year of birth in 5-year intervals and on the specific diseases included in the Charlson Comorbidity Index (CCI) and atrial fibrillation and obesity.MEASURES: The rate ratios of VTE per 1000 person-years (PY) were computed by comorbidity levels using the CCI, and interaction contrasts (IC) were calculated as a measure of the excess or deficit VTE rate not explained by the independent effects of BC and comorbidity.RESULTS: Among patients with BC with a CCI score of 1, the 0-1 year VTE rate was 12/1000 PY, and interaction accounted for 10% of the rate (IC=3.2, 95% CI 0.5 to 5.9). Among patients with BC with CCI ≥4, the VTE rate was 17, and interaction accounted for 8% of the rate (IC=1.2, 95% CI -1.8 to 4.2). There was no interaction during 2-5 years of follow-up.CONCLUSIONS: There was only little interaction between BC and the CCI score on the rate of VTE.

AB - OBJECTIVES: To assess the interaction between comorbidity and breast cancer (BC) on the rate of venous thromboembolism (VTE) beyond what can be explained by the independent effects of BC and comorbidity.DESIGN: Population-based matched cohort study.SETTING: Denmark.PARTICIPANTS: Danish patients with BC (n=62 376) diagnosed in 1995-2010 and a comparison cohort of women without BC (n=304 803) from the general population were matched to the patients with BC on year of birth in 5-year intervals and on the specific diseases included in the Charlson Comorbidity Index (CCI) and atrial fibrillation and obesity.MEASURES: The rate ratios of VTE per 1000 person-years (PY) were computed by comorbidity levels using the CCI, and interaction contrasts (IC) were calculated as a measure of the excess or deficit VTE rate not explained by the independent effects of BC and comorbidity.RESULTS: Among patients with BC with a CCI score of 1, the 0-1 year VTE rate was 12/1000 PY, and interaction accounted for 10% of the rate (IC=3.2, 95% CI 0.5 to 5.9). Among patients with BC with CCI ≥4, the VTE rate was 17, and interaction accounted for 8% of the rate (IC=1.2, 95% CI -1.8 to 4.2). There was no interaction during 2-5 years of follow-up.CONCLUSIONS: There was only little interaction between BC and the CCI score on the rate of VTE.

U2 - 10.1136/bmjopen-2014-005082

DO - 10.1136/bmjopen-2014-005082

M3 - Journal article

C2 - 24902734

SN - 2044-6055

VL - 4

SP - e005082

JO - BMJ Open

JF - BMJ Open

IS - 6

ER -

Impact of comorbidity on risk of venous thromboembolism in patients with breast cancer: a Danish population-based cohort study

Abstract

Access to Document

AUB Link

Fingerprint

Cite this